{"id":2252,"date":"2019-01-21T15:33:34","date_gmt":"2019-01-21T15:33:34","guid":{"rendered":"http:\/\/www.irlab.se\/?page_id=2252"},"modified":"2026-03-27T14:48:06","modified_gmt":"2026-03-27T13:48:06","slug":"vetenskapliga-publikationer","status":"publish","type":"page","link":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/","title":{"rendered":"Vetenskapliga publikationer"},"content":{"rendered":"\n

Vetenskapliga publikationer<\/h1>\n\n\n\n

Artiklar relaterade till mesdopetam (IRL790)<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort<\/a><\/p>\n\n\n\n

S. Oleszko, J. Tedroff, S. Waters, N. Waters. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson’s disease: A randomized phase 2b trial<\/a><\/p>\n\n\n\n

Angelo Antonini, Padraig O’Suilleabhain, Fabricio Stocchi, Johanna Landstr\u00f6m, Susanna Waters, Clas Sonesson, Joakim Tedroff<\/p>\n\n\n\n

Artikeln publicerades den 26 februari, 2025. DOI: https:\/\/doi.org\/10.1002\/mdc3.70004<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Meta-analysis of two randomized controlled trials assessing the efficacy of mesdopteam (IRL790) in levodopa-induced dyskinesia in Parkinson\u2019s disease<\/a> <\/p>\n\n\n\n

F. Hansson, E. Werner, N. Waters, J. Tedroff, S. Waters.  Poster presenterades vid MDS Congress 2024 den 29 september 2024.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

<\/p>\n\n\n\n

\"Neurotherapeutics\"<\/figure>\n<\/div>\n\n\n\n
\n

Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson’s disease psychosis<\/a> <\/p>\n\n\n\n

Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, P\u00e4r Halje, Luciano Censoni, Emilio Garro-Mart\u00ednez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson.  <\/p>\n\n\n\n

Artikeln publicerades den 19 mars, 2024. DOI: https:\/\/doi.org\/10.1016\/j.neurot.2024.e00334<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

RESULTS FROM IRL790C005 – A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY EVALUATING THE EFFICACY OF MESDOPETAM ON DAILY ON-TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON\u2019S DISEASE<\/a> <\/p>\n\n\n\n

A. ANTONINI, S. WATERS, C. SONESSON, J. LANDSTR\u00d6M, N. WATERS, J. TEDROFF.  Poster presenterades vid MDS Congress 2023 den 28 augusti 2023. <\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Behavioral and electrophysiological characterization of antipsychotic treatments in a rodent model of Parkinson\u2019s disease psychosis\u2019<\/a><\/p>\n\n\n\n

T. Loredan Stan, A. Ronaghi, S. Barrientos, P. Halje, L. Censoni, E. Garro Mart\u00ednez, E. Malinina, K. Sahlholm, P. Petersson. Poster presenterad p\u00e5 Neuroscience 2022 av Society for Neuroscience den 15 november 2022.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Behavioral and electrophysiological characterization of the antidyskinetic treatments in a rodent model of PD-LID<\/a><\/p>\n\n\n\n

A. Ronaghi, T. Loredan Stan, S. Barrientos Baeza, S. Sulis Sato, E. Malinina, L. Censoni, P. Halje, P. Petersson. Poster presenterad p\u00e5 Neuroscience 2022 av Society for Neuroscience den 15 november 2022.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers<\/a><\/p>\n\n\n\n

Sj\u00f6berg F, Waters S, L\u00f6fberg B, Sonesson C, Waters N, Tedroff J. Pharmacol Res Perspect. 2021;9:e00792. https:\/\/doi.org\/10.1002\/prp2.792.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Mesdopetam suppresses sensitization and AIMs in the rodent unilateral 6-OHDA lesion model of Parkinson\u2019s disease<\/a><\/p>\n\n\n\n

P. Svenningsson, Y. Yang, S. Hjorth, S. Waters, N. Waters, P. Svensson, J. Tedroff. Poster presented at the Society for Neuroscience Global Connectome: A virtual event on January 11, 2021.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Preclinical pharmacology of 2-(3-fluoro-5-methanesulfonylphenoxy)ethylamine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson\u2019s disease.<\/a><\/p>\n\n\n\n

Susanna Waters, Clas Sonesson, Peder Svensson, Joakim Tedroff, Manolo Carta, Elisabeth Ljung, Jenny Gunnergren, Malin Edling, Boel Svanberg, Anne Fagerberg, Johan Kullingsjo, Stephan Hjorth and Nicholas Waters. Journal of Pharmacology and Experimental Therapeutics. May 1, 2020, jpet.119.264226; DOI: https:\/\/doi.org\/10.1124\/jpet.119.264226<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia\u2014a phase 1b trial<\/a><\/p>\n\n\n\n

Per Svenningsson, Anders Johansson, Dag Nyholm, Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson and Joakim Tedroff. npj Parkinson\u2019s Disease 2018;4:35; doi:10.1038\/s41531-018-0071-3.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Artiklar relaterade till pirepemat (IRL752)<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

<\/a>Results from REACT-PD – A randomised, placebo-controlled, multi-centre phase IIB study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinsons’s disease <\/a><\/p>\n\n\n\n

J. Tedroff, F. Hansson, E. Werner, O. Vu Van, J. Landstr\u00f6m, N. Waters, C. Sonesson, N. Waters. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

<\/a>Cross-sectional analysis of interrelations between fall-rate, cognitive measures, UPDRS-subscales, and NPI-apathy in the REACT-PD study cohort<\/a><\/p>\n\n\n\n

S. Waters, F Hansson, N. Waters, J. Tedroff.  Poster presenterades vid ADPD Congress 2025 den 1-5 april, 2025.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.<\/a><\/p>\n\n\n\n

Rein\u2010Hedin E, Sj\u00f6berg F, Waters S, Sonesson C, Waters N, Huss F, Tedroff J. Clinical Pharmacology in Drug Development. 2021,0 (0);1\u201310. https:\/\/doi.org\/10.1002\/cpdd.959<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

(3S)\u20103\u2010(2,3\u2010difluorophenyl)\u20103\u2010methoxypyrrolidine (IRL752) \u2014a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent<\/a><\/p>\n\n\n\n

S. Hjorth, S. Waters, N. Waters, J. Tedroff, P. Svensson, A. Fagerberg, M. Edling, B. Svanberg, E. Ljung, J. Gunnergren, S.L. McLean, B. Grayson, N.F. Idris, J.C. Neill and C. Sonesson. The Journal of pharmacology and experimental therapeutics. DOI: https:\/\/doi.org\/10.1124\/jpet.120.000037<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson’s Disease Dementia<\/a><\/p>\n\n\n\n

Per Svenningsson MD, PhD Per Odin MD, PhD Nil Dizdar MD, PhD Anders Johansson MD, PhD Sotirios Grigoriou MD Panagiota Tsitsi MD Klas Wictorin MD, PhD Filip Bergquist MD, PhD Dag Nyholm MD, PhD Juha Rinne MD, PhD Fredrik Hansson PhD Clas Sonesson PhD Joakim Tedroff MD, PhD for the IRL752 Collaborators. Movement disorder. DOI: https:\/\/doi.org\/10.1002\/mds.28020<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson\u2019s disease dementia [abstract]<\/a><\/p>\n\n\n\n

P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff. Mov Disord. 2019; 34 (suppl 2). https:\/\/www.mdsabstracts.org\/abstract\/a-phase-iia-trial-studying-the-safety-and-tolerability-of-irl752-in-patients-with-parkinsons-disease-dementia\/. Accessed September 25, 2019.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Artiklar relaterade till IRL757<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

<\/a>IRL757C001 \u2013 A first-In-Human trial on IRL757, A cortical enhancer in clinical development for the treatment of apathy in AD\/PD<\/a><\/p>\n\n\n\n

J. Tedroff, J. Landsr\u00f6m, C. Sonesson, S. Waters, F. Hansson, B. L\u00f6fberg.  Poster presenterades vid ADPD Congress 2025 den 1-5 april, 2025.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Artiklar relaterade till ISP (Integrative Screening Process)<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"\/<\/figure>\n<\/div>\n\n\n\n
\n

<\/a>Searching for novel CNS therapies in Parkinson\u2019s and Alzheimer\u2019s disease using Integrative Screening process (ISP) : An AI\/ML driven phenotypic drug discovery platform<\/a><\/p>\n\n\n\n

S. Waters, P. Svensson, N. Waters, E. Werner, D. Andersson, F. Wallner, J. Tedroff, C. Sonnesson, S. Oleszko. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Clinical predictions in CNS drug discovery based on in vivo systems response profiles and non-linear machine learning methodology<\/a><\/p>\n\n\n\n

K. Granbom, F. Wallner, P. Svensson, S. Holm Waters, J. Kullingsj\u00f6, N. Waters, A. Andersson. Poster presented at the Society for Neuroscience Global Connectome: A virtual event on January 12, 2021.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery<\/a><\/p>\n\n\n\n

Waters S, Svensson P, Kullingsj\u00f6 J, Pont\u00e9n H, Andreasson T, Sunesson Y, Ljung E, Sonesson C, Waters N. ACS Chem Neurosci. 2017 Apr 19;8(4):785-797; doi:10.1021\/acschemneuro.6b00371.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Vetenskapliga publikationer Artiklar relaterade till mesdopetam (IRL790) Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort S. Oleszko, J. Tedroff, S. Waters, N. Waters. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026. Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson’s disease: A […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":579,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2252","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nVetenskapliga publikationer - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vetenskapliga publikationer - IRLAB\" \/>\n<meta property=\"og:description\" content=\"Vetenskapliga publikationer Artiklar relaterade till mesdopetam (IRL790) Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort S. Oleszko, J. Tedroff, S. Waters, N. Waters. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026. Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson’s disease: A […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-27T13:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/\",\"url\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/\",\"name\":\"Vetenskapliga publikationer - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg\",\"datePublished\":\"2019-01-21T15:33:34+00:00\",\"dateModified\":\"2026-03-27T13:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage\",\"url\":\"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg\",\"contentUrl\":\"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forskningsplattform\",\"item\":\"https:\/\/irlab.se\/sv\/forskningsplattform\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Vetenskapliga publikationer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vetenskapliga publikationer - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/","og_locale":"sv_SE","og_type":"article","og_title":"Vetenskapliga publikationer - IRLAB","og_description":"Vetenskapliga publikationer Artiklar relaterade till mesdopetam (IRL790) Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort S. Oleszko, J. Tedroff, S. Waters, N. Waters. Poster presenterades vid ADPD Congress 2026 den 17-21 mars, 2026. Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson’s disease: A […]","og_url":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/","og_site_name":"IRLAB","article_modified_time":"2026-03-27T13:48:06+00:00","og_image":[{"url":"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"9 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/","url":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/","name":"Vetenskapliga publikationer - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage"},"image":{"@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage"},"thumbnailUrl":"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg","datePublished":"2019-01-21T15:33:34+00:00","dateModified":"2026-03-27T13:48:06+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#primaryimage","url":"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg","contentUrl":"https:\/\/irlab.se\/wp-content\/uploads\/2026\/03\/ADPD_2026v2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/forskningsplattform\/vetenskapliga-publikationer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"Forskningsplattform","item":"https:\/\/irlab.se\/sv\/forskningsplattform\/"},{"@type":"ListItem","position":3,"name":"Vetenskapliga publikationer"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=2252"}],"version-history":[{"count":53,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2252\/revisions"}],"predecessor-version":[{"id":12908,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/2252\/revisions\/12908"}],"up":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/579"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=2252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}